Skip to main content
. 2015 Sep 10;6(32):32494–32508. doi: 10.18632/oncotarget.5572

Figure 4. Antibody production of pVAX14-treated APL mice.

Figure 4

A. pVAX14 induced antibody production to the predicted peptides. The absorbance obtained from the sera assayed on day 60 of each mouse treated with ATRA (5mg) + pVAX14 (n = 8) was normalized to values obtained from sera from mice treated with ATRA (5mg) alone (n = 3) by subtracting the ATRA alone values from those of the ATRA+pVAX14 treated group. Three of 8 mice formed antibodies to all of the peptides. Data are presented as mean +/− SEM of 3 assays; B. Anti-RARA antibody production in ATRA+pVAX14 treated APL mice compared to ATRA+Placebo treated mice. The Y-axis represents anti-RARA production expressed as follows: the ratio of specific absorbance (SA)/anti-RARA antibody 9alpha was calculated and this ratio was then divided by the median ratio obtained in control mice (ATRA alone). Increased anti-RARA antibody production in ATRA+pVAX14 treated APL mice (n = 8) compared to ATRA+Placebo treated mice (n = 11) on day 60 (p < 0.0003); nonparametric, unpaired, two tailed, Mann-Whitney test was used to compare different groups. The Prism software was used for the Mann-Whitney test analysis.